Skip to main content
. 2020 Jul 15;12(7):3895–3905.

Figure 5.

Figure 5

ECSW promotes the expressions of p-eNOS and Bcl-2 and inhibits the expressions of apoptotic factor Bax and Caspase3 through the PI3K/AKT and MEK/ERK signaling pathways. A. Western blotting analysis of AKT, p-AKT, ERK, p-ERK, P-eNOS, eNOS, Bcl-2, Bax, and caspase3 protein in EPCs. B-G. Quantification analysis of the expression levels of p-AKT, p-ERK, P-eNOS, Bcl-2, Bax, and caspase3 based on the Western blotting analysis results. the expressions of p-AKT and p-ERK were increased after ECSW treatment, the expressions of downstream signaling molecules eNOS and Bcl-2 were also increased, but the expressions of Bax and Caspase3 were decreased. However, these beneficial effects can be inhibited by PI3K/AKT inhibitor LY294002 and MEK/ERK inhibitor PD98059. Data are presented as mean ± SD. *P<0.05 vs group vehicle, #P<0.05 vs group ECSW.